Not Signed In - Phase III Trial Of Nexavar In Patients With Advanced Melanoma Does Not Meet Primary Endpoint
Tue, 05 Dec 2006 08:00 AM EST
... Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase III trial administering Nexavar(R) (sorafenib) or placebo tablets in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with advanced melanoma did not meet its primary endpoint of improving progression-free survival (PFS). [click link for full article] ...
Related Topics
- Clinical Trials
- Melanoma
- Primary
- Primary Care
- Antithrombin III
- non-Melanoma
- Pulmonary Hypertension
- Familial Dysautonomia
- Intraocular Melanoma
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Cirrhosis (Primary Biliary)
- Primary Biliary Cirrhosis
- Seizures (in about half of patients)
- What Your Female Patients Want to Know About Bladder Control
- Vaccinations For HIV/AIDs Patients
- Primary hyperoxaluria
- Smoking Cessation and Continued Risk in Cancer Patients
- Congenital antithrombin III deficiency
- Approximately one-half of patients with small tumors will get back useful hearing in the affected ear after surgery.
email this page
print this page
bookmark this page
feedback on this page
